Why VCs keep passing on your biotech startup (and it is not the science)

Why a good meeting with a VC partner does not lead to a term sheet

The single most underappreciated structural fact about venture capital decision-making is this: the partner who meets you is not the person who decides. Every significant investment goes to an investment committee where partners who were not in the room evaluate the opportunity based entirely on how the attending partner describes it. That description happens without you, based on notes taken in a thirty-minute meeting, competing for attention against five other deals that week.

This creates a specific failure mode. A founder who delivers a compelling pitch to an engaged partner may still receive a pass because the partner could not summarise the investment thesis convincingly to their colleagues. Not because the opportunity was weak, but because the pitch was built to impress, not to be repeated. The information was dense, the science was intricate, and the logic required context that only someone who had heard the full presentation could follow.

The test is simple and brutal: after one hearing, can the partner explain your thesis, your lead milestone, your exit scenario, and your ask in under two minutes to colleagues who know nothing about your company? If the answer is no, the pitch is not ready, regardless of how strong the science is. Most biotech pitches fail this test because they are built to impress the person in the room, not to be repeated by them.

A VC investment is not decided in the meeting with the founder. It is decided in the partnership meeting that follows. Build the pitch for the room you will never be in.

You are solving the wrong problem first

The most common and most expensive sequencing error in biotech fundraising is addressing the least important gating uncertainty first. Development plans are frequently built around the questions founders find most scientifically interesting, the experiments that are next on the inherited timeline, or the milestones that satisfy grant reporting requirements. None of these criteria are investor criteria.

Investors use a framework called risk-adjusted net present value, or rNPV, to value early-stage biotech assets. The calculation multiplies estimated peak revenues by the cumulative probability of reaching market. Because risks are multiplicative rather than additive, a weakness in one component, whether clinical, regulatory, manufacturing, or IP, depresses total expected value disproportionately. Resolving the highest-leverage uncertainty first produces a much larger valuation step-up than resolving three lower-leverage uncertainties for the same total cost.

The practical implication is that a development plan built around scientific interest is almost always solving the wrong problem first from an investor's perspective. The question that should organise every capital allocation decision is specific: which single uncertainty, retired with the available capital, moves the cumulative probability of a deal by the most? Founders who cannot answer that question clearly before walking into an investor meeting are presenting a research programme, not an investment opportunity.

Your milestone map describes activities, not value creation

A milestone map that lists activities produces a timeline. A milestone map that lists value inflection points produces an investment thesis. The difference is decisive, and investors distinguish between the two in the first sixty seconds of reading the deck.

An activity milestone is: Complete IND-enabling studies in Q3. A value inflection point is: Generate the safety and efficacy data package that removes the primary barrier to a pharma in-licensing conversation and positions the asset for a Series B at approximately three times the current valuation, based on comparable transactions in this indication. These describe the same event. One tells the investor what you will do. The other tells them what it will be worth when you have done it, and why.

The reframe requires knowing which pharma companies would consider licensing the asset at the next inflection point, what evidence package they require to initiate that conversation, and what comparable transactions in the same indication and modality suggest about valuation at that stage. Most founders have not done that analysis. The ones who have arrive at investor meetings with a different kind of conversation.

The reframe from activity milestone to value inflection point starts with a different document: not the pitch deck, but the equity story that sits underneath it. The equity story is not a pitch. It is a thesis.

You are pitching the wrong fund

Venture capital funds are not interchangeable pools of capital. Each fund has a thesis built over years of portfolio construction: specific modalities it understands, development stages at which it typically leads, geographies in which it has operational capability, and exit relationships it has built with pharma business development teams. A pitch that fits the thesis is evaluated on its merits. A pitch that asks the fund to step outside its thesis requires the partnership to build new conviction from scratch, which almost never happens.

The thesis is not always stated explicitly, but it is always legible. Three to five portfolio companies read carefully reveal the modality concentration, the typical entry stage, and the acquirers who have appeared in the fund's exit record. Those acquirers are the fund's most valuable strategic relationships. A company whose asset could generate a conversation with one of those acquirers is, to that fund, more interesting than a scientifically superior asset that leads nowhere in the fund's existing relationship network.

Every fund also pursues three simultaneous objectives that most founders address only partially. The return objective: what financial return does the fund need to generate, within what time horizon, given where the fund is in its deployment cycle. A fund in year seven of a ten-year life is evaluating your company against a much shorter exit window than a fund in year two, regardless of how both describe themselves as early-stage investors. The portfolio objective: what gap in the existing portfolio does this investment fill, and why is now the right moment to fill it. The relationship objective: which strategic relationships does this investment strengthen. Founders who understand all three build pitches that solve the fund's problem, not just their own.

Pitching the wrong fund with a perfect pitch is not a fundraising strategy. It is an expensive way to close doors that are difficult to reopen.

Why European biotech fundraising has an additional layer of complexity

European venture capital in life sciences operates under structural constraints that amplify each of the problems described above, and adds several that are specific to the regional market. The numbers make the structural gap concrete: European life sciences VC funds account for just 7% of the global market, compared with 63% in the US and 14% in China, according to the European Life Sciences Coalition (ELSC, February 2026). EU pension funds allocate approximately 0.02% of assets to life sciences VC, against roughly 2% in the US. The capital shortage is not a perception. It is arithmetic.

European funds are smaller. The average deal size across European biotech rounds is approximately 31 million euros, compared to 53 million euros for equivalent US rounds, according to the Biotech Finance Report 2023. Smaller tickets mean European VCs need to be more selective about development stage and de-risking before committing. A US fund can afford to take a position at preclinical stage because the ticket is large enough to carry the asset through multiple inflection points. A European fund backing the same asset at the same stage is proportionally more exposed if the first inflection point produces ambiguous data.

European investment decisions are more consensus-driven. Most significant European life sciences VC investments require full partnership approval rather than a single partner's conviction. This makes the problem of pitching for a room you will never be in more acute: the attending partner needs to bring not just enthusiasm but a complete, self-sufficient investment case that can survive a rigorous challenge from partners who know the sector well and have strong opinions about risk.

European funds have fewer comparable exits to reference. The structural exit gap is stark: 66 of 67 EU biotech companies that went public over the past six years listed outside the European Union, according to the ELSC (February 2026). The US market has decades of biotech M&A and IPO data that provides reliable benchmarks for valuation at each development stage. European biotech has a shorter exit history and a smaller pool of comparables, which makes valuation discussions more subjective and due diligence more time-consuming. Founders who cite US comparables without adjusting for the European discount are presenting data that experienced European investors will immediately challenge.

Finally, European biotech fundraising is more dependent on non-dilutive capital sequencing than its US counterpart. The EIC Accelerator, national grant programmes, and regional innovation funds provide capital that de-risks assets before equity conversations begin. A European biotech founder who has not mapped the grant landscape before approaching VCs is arriving at those conversations without the leverage that public capital provides. A well-sequenced capital strategy, grants first, equity second, demonstrates the capital efficiency that European investors specifically reward.

The Magnet Effect: why the first lead investor is the hardest

The European life sciences VC landscape is more fragmented than it appears. The number of funds nominally active in European biotech is large. The number capable of leading a round across geographies, independently of where the asset or the founding team is based, is considerably smaller. Most funds in Europe have been built around national ecosystems: their LP base, their deal flow, and their operational networks are concentrated within a single country or region. This is not a strategic choice so much as a structural reality of how the European venture market developed.

The practical consequence for founders is that the realistic pool of potential lead investors for a cross-border European biotech deal is much smaller than a database search suggests. Finding twenty funds that list European life sciences as an investment area is not the same as finding twenty funds that would lead a round in an Italian oncology spinout or a Danish genomics company.

What changes the dynamic is when one of the genuinely pan-European funds, those with the network, the credibility, and the cross-border LP relationships to lead independently of geography, decides to move first. That decision functions as a market signal. It reduces the uncertainty for other funds, who can follow a lead investor whose due diligence they respect rather than building conviction from scratch. The lead investor does not just bring capital. It brings the credibility that makes other capital possible.

The strategic implication for European biotech founders is specific: the target is not a long list of interested investors. It is identifying the one fund whose lead position would function as a magnet for the others. That fund is worth disproportionate effort to reach, prepare for, and align with before approaching anyone else. A round that closes around a strong pan-European lead closes faster and on better terms than one assembled from a fragmented group of cautious followers with no anchor.

The re-approach trap

One of the most common and least discussed mistakes in biotech fundraising is returning to a fund that has already passed without a fundamental change in the investment case. Founders interpret keep us posted as an invitation to return when new data arrives. In most cases, it is a polite close.

A fund that passes on an investment files a mental assessment. That assessment can be updated, but the bar for updating it is high. New preclinical data at a similar stage to what was previously presented does not clear the bar. A completed Phase 1 with clean safety data at a materially different valuation might. A pharma letter of intent at a stage the fund had previously assessed as too early for a pharma conversation certainly does. The principle is that the investment case must have changed structurally, not just progressed incrementally, for a re-approach to open a different conversation.

The more useful discipline is to understand precisely why a fund passed before deciding whether to re-approach. There are three distinct types of pass, and they require different responses. A thesis pass, where the fund's modality, stage, or geography does not accommodate the asset, is permanent and should be accepted cleanly. A timing pass, where the fund is at a point in its deployment cycle that makes early-stage positions difficult, is temporary and worth tracking. A preparation pass, where the investment case was not complete enough to take to investment committee, is the only category that justifies rebuilding the case and returning.

Frequently asked questions